Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
AstraZeneca
University of Michigan Rogel Cancer Center
BeOne Medicines
Bayer
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
ViroMissile, Inc.
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
Seagen Inc.
AstraZeneca
Tizona Therapeutics, Inc
Essen Biotech
Ulsan University Hospital
NiKang Therapeutics, Inc.
Brigham and Women's Hospital
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Iambic Therapeutics, Inc
AstraZeneca
Vanderbilt-Ingram Cancer Center
DualityBio Inc.
Daiichi Sankyo
SN BioScience
Takeda
Second Life Therapeutics
Ocellaris Pharma, Inc.
Innate Pharma
Var2 Pharmaceuticals
GlaxoSmithKline
Mayo Clinic
Tanabe Pharma America, Inc.
European Institute of Oncology
Hospices Civils de Lyon
BicycleTx Limited
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
SystImmune Inc.
AbbVie
Rondo Therapeutics
SillaJen, Inc.
Actym Therapeutics, Inc.
NiKang Therapeutics, Inc.
LigaChem Biosciences, Inc.
Bolt Biotherapeutics, Inc.